In this context, BRCA1/2 testing on tumor tissues could be combined with other biomarker evaluations, thus saving time and biological materials and allowing us to identify a higher number of patients eligible for available targeted therapies or to be enrolled in ongoing clinical trials. The gene discussed is BRCA1; the disease is neoplasm.